Victoria brings extensive expertise in drug development and regulatory affairs, honed over years of increasing responsibility in global regulatory roles at leading pharmaceutical companies such as Bristol Myers Squibb (BMS), Merck, and GlaxoSmithKline (GSK). Most recently, she served as the Senior Vice President of Global Regulatory Affairs at Adlai Nortye, USA, Inc., where she was a member of the executive leadership team and was responsible for global regulatory strategy and execution in support of the company’s portfolio.

Victoria has been instrumental in securing regulatory approval for numerous high-impact therapies across multiple therapeutic areas, including NULOJIX®, ORENCIA®, ELIQUIS®, MARIZEV®, JANUVIA®, JANUMET®, JANUMET XR®, and the groundbreaking cancer immunotherapy KEYTRUDA®. She holds a Bachelor of Science in Biochemistry from the University of Vermont and earned her PhD in Pharmacology and Toxicology from the University of Kansas.